Sarah Ryan, MD
Urology · Las Vegas, NVNPI 1659328391
Payments from drug & device makers
What this record shows
14 manufacturers reported payments, led by Medtronic at 57.8% of the total. Reporting peaked in 2019 at $2,721 and has fallen 88.7% since, to $308 in 2025.
Across 92 payments — averaging $71.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Axonics, Inc.$2K
- Caldera Medical, Inc$194
- Pfizer$155
- Coloplast$113
- AbbVie$101
- plus $308 from 8 others
Across 1 payment — averaging $532.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$533
What the payments were for
- Travel & lodging$2,96845%
- Food & beverage$3,62855%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 30 | $3,813 |
| Axonics, Inc. | 24 | $1,912 |
| Caldera Medical, Inc | 1 | $194 |
| Pfizer | 9 | $155 |
| Coloplast | 4 | $113 |
| AbbVie(2 entities) | 7 | $101 |
| Astellas Pharma US Inc | 5 | $93 |
| Boston Scientific | 5 | $92 |
| Therapeuticsmd, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Dendreon Pharmaceuticals LLC | 1 | $21 |
| Novartis | 1 | $19 |
| Duchesnay USA Incorporated | 1 | $18 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$2,859
- Bulkamid$1,262
- Axonics r-SNM System$1,150
- Axonics$128
How this compares
$6,596 in reported general payments places this provider in the 55th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 123 | $85,483 |
| GemtesaVibegron | 93 | $58,075 |
| Estradiol | 153 | $9,883 |
| Solifenacin Succinate | 67 | $2,538 |
| Trimethoprim | 28 | $1,350 |
| Tamsulosin Hcl | 67 | $828 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 121 | $636 |
| Cephalexin | 125 | $379 |
| NitrofurantoinNitrofurantoin Macrocrystal | 14 | $329 |
| Oxybutynin Chloride ErOxybutynin Chloride | 22 | $220 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 43 | $137 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 56 | $132 |
| Ciprofloxacin Hcl | 25 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $93 | $85,483123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 63 urology providers in Nevada.
Other urology in Las Vegas
- Vijay GoliLas Vegas$105K
- Joel AbbottLas Vegas$69K
- Victor GrigorievLas Vegas$59K
- Omid LesaniLas Vegas$27K
- Joseph CandelaLas Vegas$24K
- Lawrence NewmanLas Vegas$22K
- Michael VerniLas Vegas$16K
- Mulugeta KassahunLas Vegas$13K
- Jason ZommickLas Vegas$12K
- Ilya GorbachinskyLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.